This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsigos, C. Articles by Chrousos, G. P. Search for Related Content PubMed PubMed Citation Articles by Tsigos, C. Articles by Chrousos, G. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCAGON

Dose-Dependent Effects of Recombinant Human Interleukin-6 on Glucose Regulation

Developmental Endocrinology Branch (C.T., D.A.P., R.D., C.S.M., G.P.C.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; and Hellenic National Center for Research, Prevention and Treatment of Diabetes Mellitus and its Complications (C.T., I.K.), Athens 106 75, Greece

Address all correspondence and requests for reprints to: Constantine Tsigos, M.D., Ph.D., Hellenic National Diabetes Center, 3 Ploutarchou Street, 106 75 Athens, Greece.

Inflammatory cytokines have metabolic actions that probably contribute to the general adaptation of the organism during infectious or inflammatory stress. To examine the effects of interleukin 6 (IL-6), the main circulating cytokine, on glucose metabolism in man, we performed dose-response studies of recombinant human IL-6 in normal volunteers. Increasing single doses of IL-6 (0.1, 0.3, 1.0, 3.0, and 10.0 mg/Kg BW) were injected sc in 15 healthy male volunteers (3 in each dose) after a 12-h fast. All IL-6 doses were tolerated well and produced no significant adverse effects. We measured the circulating levels of glucose, insulin, C-peptide, and glucagon at baseline and half-hourly over 4 h after the IL-6 injection. Mean peak plasma levels of IL-6 were achieved between 120 and 240 min and were 8, 22, 65, 290, and 4050 pg/mL, respectively, for the 5 doses. After administration of the 2 smaller IL-6 doses, we observed no significant changes in plasma glucose levels, which, because of continued fasting, decreased slightly over time. By 60 min after the 3 higher IL-6 doses, however, the decline in fasting blood glucose was arrested, and glucose levels increased in a dose-dependent fashion. The concurrent levels of plasma insulin and C-peptide were not affected by any IL-6 dose. In contrast, IL-6 caused significant increases in plasma glucagon levels, which peaked between 120 and 150 min after the IL-6 injection. In conclusion, sc IL-6 administration induced dose-dependent increases in fasting blood glucose, probably by stimulating glucagon release and other counteregulatory hormones and/or by inducing peripheral resistance to insulin action.

This article has been cited by other articles:

				G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., September 5, 2008; (2008) ehn387v1. [Abstract] [Full Text] [PDF]

				S. Dotson, R. Freeman, H. J. Failing, and G. K. Adler Hypoglycemia Increases Serum Interleukin-6 Levels in Healthy Men and Women Diabetes Care, June 1, 2008; 31(6): 1222 - 1223. [Abstract] [Full Text] [PDF]

				J.-H. Kim, J. E. Kim, H.-Y. Liu, W. Cao, and J. Chen Regulation of Interleukin-6-induced Hepatic Insulin Resistance by Mammalian Target of Rapamycin through the STAT3-SOCS3 Pathway J. Biol. Chem., January 11, 2008; 283(2): 708 - 715. [Abstract] [Full Text] [PDF]

				M. G. Cree and R. R. Wolfe Postburn trauma insulin resistance and fat metabolism Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E1 - E9. [Abstract] [Full Text] [PDF]

				D. Simon, A.-M. Prieur, P. Quartier, J. Charles Ruiz, and P. Czernichow Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2567 - 2573. [Abstract] [Full Text] [PDF]

				M. Qatanani and M. A. Lazar Mechanisms of obesity-associated insulin resistance: many choices on the menu Genes & Dev., June 15, 2007; 21(12): 1443 - 1455. [Abstract] [Full Text] [PDF]

				L. Fontana, J. C. Eagon, M. E. Trujillo, P. E. Scherer, and S. Klein Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans Diabetes, April 1, 2007; 56(4): 1010 - 1013. [Abstract] [Full Text] [PDF]

				S. G. Park, Y. S. Kang, J. Y. Kim, C. S. Lee, Y. G. Ko, W. J. Lee, K.-U. Lee, Y. I. Yeom, and S. Kim Hormonal activity of AIMP1/p43 for glucose homeostasis PNAS, October 3, 2006; 103(40): 14913 - 14918. [Abstract] [Full Text] [PDF]

				I. Wernstedt, A. Edgley, A. Berndtsson, J. Faldt, G. Bergstrom, V. Wallenius, and J.-O. Jansson Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R551 - R557. [Abstract] [Full Text] [PDF]

				N. de Rekeneire, R. Peila, J. Ding, L. H. Colbert, M. Visser, R. I. Shorr, S. B. Kritchevsky, L. H. Kuller, E. S. Strotmeyer, A. V. Schwartz, et al. Diabetes, Hyperglycemia, and Inflammation in Older Individuals: The Health, Aging and Body Composition study Diabetes Care, August 1, 2006; 29(8): 1902 - 1908. [Abstract] [Full Text] [PDF]

				A. Natali, E. Toschi, S. Baldeweg, D. Ciociaro, S. Favilla, L. Sacca, and E. Ferrannini Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes, April 1, 2006; 55(4): 1133 - 1140. [Abstract] [Full Text] [PDF]

				C. Weigert, A. M. Hennige, R. Lehmann, K. Brodbeck, F. Baumgartner, M. Schauble, H. U. Haring, and E. D. Schleicher Direct Cross-talk of Interleukin-6 and Insulin Signal Transduction via Insulin Receptor Substrate-1 in Skeletal Muscle Cells J. Biol. Chem., March 17, 2006; 281(11): 7060 - 7067. [Abstract] [Full Text] [PDF]

				O. P. Kristiansen and T. Mandrup-Poulsen Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent? Diabetes, December 1, 2005; 54(suppl_2): S114 - S124. [Abstract] [Full Text] [PDF]

				S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E586 - E590. [Abstract] [Full Text] [PDF]

				D. Bach, D. Naon, S. Pich, F. X. Soriano, N. Vega, J. Rieusset, M. Laville, C. Guillet, Y. Boirie, H. Wallberg-Henriksson, et al. Expression of Mfn2, the Charcot-Marie-Tooth Neuropathy Type 2A Gene, in Human Skeletal Muscle: Effects of Type 2 Diabetes, Obesity, Weight Loss, and the Regulatory Role of Tumor Necrosis Factor {alpha} and Interleukin-6 Diabetes, September 1, 2005; 54(9): 2685 - 2693. [Abstract] [Full Text] [PDF]

				C. Weigert, A. M. Hennige, K. Brodbeck, H. U. Haring, and E. D. Schleicher Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E251 - E257. [Abstract] [Full Text] [PDF]

				A. Margeli, K. Skenderi, M. Tsironi, E. Hantzi, A.-L. Matalas, C. Vrettou, E. Kanavakis, G. Chrousos, and I. Papassotiriou Dramatic Elevations of Interleukin-6 and Acute-Phase Reactants in Athletes Participating in the Ultradistance Foot Race Spartathlon: Severe Systemic Inflammation and Lipid and Lipoprotein Changes in Protracted Exercise J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3914 - 3918. [Abstract] [Full Text] [PDF]

				L. Rosendal, K. Sogaard, M. Kjaer, G. Sjogaard, H. Langberg, and J. Kristiansen Increase in interstitial interleukin-6 of human skeletal muscle with repetitive low-force exercise J Appl Physiol, February 1, 2005; 98(2): 477 - 481. [Abstract] [Full Text] [PDF]

				M. Fasshauer, J. Klein, S. Kralisch, M. Klier, U. Lossner, M. Bluher, and R. Paschke Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes J. Endocrinol., December 1, 2004; 183(3): 561 - 567. [Abstract] [Full Text] [PDF]

				G. B. Di Gregorio, L. Hensley, T. Lu, G. Ranganathan, and P. A. Kern Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E182 - E187. [Abstract] [Full Text] [PDF]

				M. A. Febbraio, N. Hiscock, M. Sacchetti, C. P. Fischer, and B. K. Pedersen Interleukin-6 Is a Novel Factor Mediating Glucose Homeostasis During Skeletal Muscle Contraction Diabetes, July 1, 2004; 53(7): 1643 - 1648. [Abstract] [Full Text] [PDF]

				C. Weigert, K. Brodbeck, H. Staiger, C. Kausch, F. Machicao, H. U. Haring, and E. D. Schleicher Palmitate, but Not Unsaturated Fatty Acids, Induces the Expression of Interleukin-6 in Human Myotubes through Proteasome-dependent Activation of Nuclear Factor-{kappa}B J. Biol. Chem., June 4, 2004; 279(23): 23942 - 23952. [Abstract] [Full Text] [PDF]

				J. Faldt, I. Wernstedt, S. M. Fitzgerald, K. Wallenius, G. Bergstrom, and J.-O. Jansson Reduced Exercise Endurance in Interleukin-6-Deficient Mice Endocrinology, June 1, 2004; 145(6): 2680 - 2686. [Abstract] [Full Text] [PDF]

				A. G. Pittas, N. A. Joseph, and A. S. Greenberg Adipocytokines and Insulin Resistance J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 447 - 452. [Full Text] [PDF]

				P. J. Klover, T. A. Zimmers, L. G. Koniaris, and R. A. Mooney Chronic Exposure to Interleukin-6 Causes Hepatic Insulin Resistance in Mice Diabetes, November 1, 2003; 52(11): 2784 - 2789. [Abstract] [Full Text] [PDF]

				K. Stenlof, I. Wernstedt, T. Fjallman, V. Wallenius, K. Wallenius, and J.-O. Jansson Interleukin-6 Levels in the Central Nervous System Are Negatively Correlated with Fat Mass in Overweight/Obese Subjects J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4379 - 4383. [Abstract] [Full Text] [PDF]

				M. A. Febbraio, P. Ott, H. B. Nielsen, A. Steensberg, C. Keller, P. Krustrup, N. H. Secher, and B. K. Pedersen Hepatosplanchnic clearance of interleukin-6 in humans during exercise Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E397 - E402. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]

				S. Chia, M. Qadan, R. Newton, C. A. Ludlam, K. A.A. Fox, and D. E. Newby Intra-Arterial Tumor Necrosis Factor-{alpha} Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 695 - 701. [Abstract] [Full Text] [PDF]

				J. J. Senn, P. J. Klover, I. A. Nowak, and R. A. Mooney Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes Diabetes, December 1, 2002; 51(12): 3391 - 3399. [Abstract] [Full Text] [PDF]

				K. Esposito, F. Nappo, R. Marfella, G. Giugliano, F. Giugliano, M. Ciotola, L. Quagliaro, A. Ceriello, and D. Giugliano Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress Circulation, October 15, 2002; 106(16): 2067 - 2072. [Abstract] [Full Text] [PDF]

				M. A. FEBBRAIO and B. K. PEDERSEN Muscle-derived interleukin-6: mechanisms for activation and possible biological roles FASEB J, September 1, 2002; 16(11): 1335 - 1347. [Abstract] [Full Text] [PDF]

				A.D. Pradhan and P.M. Ridker Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J., June 1, 2002; 23(11): 831 - 834. [Full Text] [PDF]

				O. Ronsen, T. Lea, R. Bahr, and B. K. Pedersen Enhanced plasma IL-6 and IL-1ra responses to repeated vs. single bouts of prolonged cycling in elite athletes J Appl Physiol, June 1, 2002; 92(6): 2547 - 2553. [Abstract] [Full Text] [PDF]

				I. Kosmidou, T. Vassilakopoulos, A. Xagorari, S. Zakynthinos, A. Papapetropoulos, and C. Roussos Production of Interleukin-6 by Skeletal Myotubes . Role of Reactive Oxygen Species Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 587 - 593. [Abstract] [Full Text] [PDF]

				V. Mohamed-Ali, L. Flower, J. Sethi, G. Hotamisligil, R. Gray, S. E. Humphries, D. A. York, and J. Pinkney {beta}-Adrenergic Regulation of IL-6 Release from Adipose Tissue: In Vivo and in Vitro Studies J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5864 - 5869. [Abstract] [Full Text] [PDF]

				A. Steensberg, A. D. Toft, P. Schjerling, J. Halkjar-Kristensen, and B. K. Pedersen Plasma interleukin-6 during strenuous exercise: role of epinephrine Am J Physiol Cell Physiol, September 1, 2001; 281(3): C1001 - C1004. [Abstract] [Full Text] [PDF]

				A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus JAMA, July 18, 2001; 286(3): 327 - 334. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, M. Vayreda, C. Richart, C. Gutierrez, M. Broch, J. Vendrell, and W. Ricart Circulating Interleukin 6 Levels, Blood Pressure, and Insulin Sensitivity in Apparently Healthy Men and Women J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1154 - 1159. [Abstract] [Full Text]

				J.-P. Bastard, C. Jardel, E. Bruckert, P. Blondy, J. Capeau, M. Laville, H. Vidal, and B. Hainque Elevated Levels of Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after Weight Loss J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3338 - 3342. [Abstract] [Full Text]

				A. Inui Cancer Anorexia-Cachexia Syndrome: Are Neuropeptides the Key? Cancer Res., September 1, 1999; 59(18): 4493 - 4501. [Abstract] [Full Text] [PDF]

				C. Tsigos, I. Kyrou, G. P. Chrousos, and D. A. Papanicolaou Prolonged Suppression of Corticosteroid-Binding Globulin by Recombinant Human Interleukin-6 in Man J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3379 - 3379. [Full Text]